Monograph of Vitamin K (Phytomenadione)

Introduction

Vitamin K, specifically phytomenadione, is a fat‑soluble vitamin essential for blood coagulation, bone metabolism, and cellular signaling. As a key cofactor for gamma‑glutamyl carboxylase (GGCX), it facilitates the post‑translational modification of clotting proteins, enabling their interaction with calcium ions. The term “phytomenadione” refers to the plant‑derived form of vitamin K, distinguished from menadione, the synthetic analogue. Clinically, vitamin K is administered orally or intravenously to correct deficiencies, reverse anticoagulant therapy, and manage bleeding disorders. Understanding its pharmacokinetics, mechanisms of action, and therapeutic implications is crucial for healthcare professionals involved in medication management, especially where anticoagulation therapy intersects with other pharmacological agents.

Learning objectives for this chapter include:

• Defining the molecular structure and classification of phytomenadione.
• Describing the pharmacokinetic characteristics and metabolic pathways.
• Explaining the biochemical role of vitamin K in gamma‑carboxylation.
• Identifying clinical scenarios where vitamin K is indicated or contraindicated.
• Integrating knowledge of drug interactions with vitamin K into therapeutic decision‑making.

Fundamental Principles

Core Concepts and Definitions

Vitamin K is a group of naphthoquinones that share a core structure of a naphthoquinone ring with varying substituents. Phytomenadione (vitamin K₁) possesses a phytyl side chain that facilitates its incorporation into cell membranes and lipoproteins. Menadione (vitamin K₃) lacks this side chain and is largely synthetic. Vitamin K₂ (menaquinones) contains a variable isoprenoid side chain, with MK‑4 and MK‑7 being the most studied subtypes. For the purposes of this monograph, emphasis is placed on phytomenadione given its predominance in dietary sources and clinical use.

Theoretical Foundations

The biological activity of vitamin K depends on its redox cycling between the quinone and hydroquinone forms. The hydroquinone is the active cofactor for GGCX, which catalyzes the conversion of glutamate residues to gamma‑carboxyglutamate (Gla) on clotting factors II, VII, IX, and X, as well as proteins C and S. This post‑translational modification creates high‑affinity calcium binding sites, enabling the assembly of the prothrombinase complex on phospholipid surfaces. The rate of carboxylation is proportional to the concentration of the vitamin K hydroquinone, illustrating a direct pharmacodynamic relationship.

Key Terminology

• Phytomenadione (Vitamin K₁) – Plant‑derived naphthoquinone with a phytyl side chain.
• Gamma‑glutamyl carboxylase (GGCX) – Enzyme responsible for carboxylation of glutamate residues.
• Gamma‑carboxyglutamate (Gla) – Post‑translationally modified residue that binds calcium.
• Half‑life (t_1/2) – Time required for the plasma concentration to reduce by 50 %.
• Clearance (Cl) – Volume of plasma from which the drug is completely removed per unit time.
• Area Under the Curve (AUC) – Integral of plasma concentration over time.

Detailed Explanation

Chemical Structure and Classification

Phytomenadione comprises a naphthoquinone core (1,4‑naphthoquinone) substituted at positions 2 and 3 with methyl groups and at position 4 with a phytyl side chain (C₂₀H₄₀). The lipophilic nature of the phytyl chain confers strong affinity for low‑density lipoprotein particles, facilitating intestinal absorption via micellar incorporation. The structure is illustrated in Figure 1 (textual representation). The presence of the quinone ring allows reversible redox reactions essential for its cofactor role.

Biosynthesis and Dietary Sources

In humans, endogenous production of vitamin K occurs via bacterial fermentation in the colon, predominantly by species such as Clostridium spp. The amount produced is variable and depends on gut microbiota composition and diet. Dietary intake is a significant contributor, with leafy greens (kale, spinach), cruciferous vegetables, and certain oils providing high vitamin K₁ content. Fortified foods and supplements also contribute. The recommended dietary allowance (RDA) for adults is approximately 90–120 µg per day, although therapeutic dosing for deficiency correction often exceeds these amounts by several fold.

Absorption, Distribution, Metabolism, and Elimination (ADME)

Oral absorption of phytomenadione is facilitated by bile salts, which solubilize the lipophilic molecule into mixed micelles. The efficiency of absorption can be influenced by factors such as dietary fat intake, gastrointestinal motility, and concurrent medications that alter bile flow. Once absorbed, vitamin K becomes incorporated into chylomicrons and is transported via the lymphatic system to the circulation. Distribution is largely associated with lipoprotein particles; approximately 80 % of plasma vitamin K is bound to lipoproteins, while the remainder circulates in the free form.

Metabolism primarily occurs in the liver via oxidation of the hydroquinone back to the quinone form. This redox cycle is essential for maintaining the pool of active cofactor. The liver also conjugates vitamin K for excretion, contributing to biliary elimination. Renal excretion is minimal because of the lipophilic nature of the molecule. The terminal half‑life of phytomenadione is relatively long, ranging from 30 h to 70 h, depending on the dose and patient characteristics. Pharmacokinetic parameters can be summarized as follows:

Parameter	Typical Value
Cmax	≈ 0.5–1.0 µg/mL (oral 10 mg)
tmax	≈ 4–6 h
t1/2	≈ 30–70 h
Cl	≈ 0.05–0.1 L/h/kg
AUC	Dose ÷ Cl

The relationship AUC = Dose ÷ Cl illustrates the linear pharmacokinetics observed for therapeutic doses. In practice, dosing adjustments are made for patients with hepatic impairment, as reduced clearance can lead to accumulation and increased risk of bleeding when combined with anticoagulants.

Role in Gamma‑Carboxylation

The enzymatic carboxylation reaction mediated by GGCX can be represented as:

Glutamate residue + CO₂ + vitamin K hydroquinone + NADPH → Gamma‑carboxyglutamate (Gla) + vitamin K quinone + NADP⁺

The vitamin K hydroquinone acts as an electron donor, reducing the quinone form while facilitating the addition of CO₂ to the glutamate side chain. The regenerated quinone is then reduced back to the hydroquinone, completing the catalytic cycle. The efficiency of this cycle is dependent on the intracellular concentration of vitamin K hydroquinone, which is modulated by absorption, metabolism, and drug interactions.

Mathematical Relationships and Models

Pharmacokinetic modeling often employs a one‑compartment model with first‑order absorption and elimination. The concentration–time profile is expressed as:

C(t) = (F × Dose ÷ V_d) × [k_a ÷ (k_a – k_el)] × (e^−k_elt – e^−k_at)

where F is the absolute bioavailability, k_a is the absorption rate constant, k_el is the elimination rate constant, and V_d is the apparent volume of distribution. For intravenous administration, absorption is instantaneous, simplifying the equation to:

C(t) = (Dose ÷ V_d) × e^−k_elt

The t_1/2 can be derived from k_el using:

t_1/2 = ln(2) ÷ k_el

These relationships aid in predicting concentration profiles and optimizing dosing regimens.

Factors Affecting the Process

• Gastrointestinal Factors – Alterations in pH, motility, or bile secretion can reduce absorption.
• Drug Interactions – Antibiotics that suppress gut flora diminish endogenous vitamin K synthesis; anticoagulants such as warfarin inhibit GGCX activity; statins may interfere with vitamin K metabolism.
• Genetic Polymorphisms – Variants in the VKORC1 gene (vitamin K epoxide reductase complex subunit 1) influence sensitivity to warfarin.
• Renal and Hepatic Function – Hepatic impairment reduces clearance; renal impairment has minimal direct effect but may alter overall pharmacokinetics.
• Age and Body Composition – Elderly patients often exhibit altered distribution and slower clearance.

Clinical Significance

Relevance to Drug Therapy

Vitamin K is integral to the management of patients on vitamin K antagonists (VKAs) such as warfarin and acenocoumarol. The therapeutic goal is to maintain an international normalized ratio (INR) within a narrow therapeutic window. Over‑correction with vitamin K can precipitate thrombosis, whereas under‑correction can lead to bleeding. The dose of vitamin K required to reverse anticoagulation is dose‑dependent: 1 mg for minor INR elevation, 5 mg for severe elevation, and 10 mg for life‑threatening hemorrhage. Intravenous administration is preferred in emergencies due to rapid onset.

Practical Applications

• Deficiency Management – Neonatal hypoprothrombinemia, chronic liver disease, malabsorption syndromes, and prolonged use of broad‑spectrum antibiotics are indications for vitamin K supplementation.
• Reversal of Anticoagulation – Acute reversal of warfarin therapy in the setting of bleeding, invasive procedures, or critical illness.
• Prophylaxis – Oral vitamin K is used in patients on long‑term VKA therapy to reduce the risk of spontaneous hemorrhage.
• Adjunctive Therapy – In patients receiving anticoagulants, concomitant administration of low‑dose vitamin K can mitigate the risk of supratherapeutic INR while preserving anticoagulant efficacy.

Clinical Examples

In a 68‑year‑old woman on warfarin for atrial fibrillation presenting with a spontaneous intracranial hemorrhage, intravenous vitamin K 10 mg is administered over 15 min. Serial INR measurements reveal a return to the therapeutic range within 24 h. Subsequent imaging confirms resolution of the hemorrhage. This case illustrates the critical role of prompt vitamin K administration in life‑threatening bleeding.

Clinical Applications/Examples

Case Scenario 1 – Neonatal Vitamin K Deficiency

A term infant born to a mother with chronic liver disease presents with a prolonged prothrombin time (PT) and elevated INR. The infant receives an intramuscular injection of vitamin K 1 mg. Within 24 h, coagulation parameters normalize, and the infant is discharged with a recommendation for routine oral vitamin K supplementation. This scenario underscores the necessity of prophylactic vitamin K in high‑risk neonates.

Case Scenario 2 – Surgical Anticoagulation Management

A 55‑year‑old man scheduled for elective orthopedic surgery is on warfarin therapy. His pre‑operative INR is 3.5. The surgical team administers an oral vitamin K 1 mg and a single dose of intravenous unfractionated heparin to bridge therapy. INR returns to 1.8 within 8 h, allowing surgery to proceed without bleeding complications. Post‑operatively, warfarin is restarted with careful INR monitoring. This illustrates the use of vitamin K as part of a bridging protocol.

Case Scenario 3 – Drug Interaction with Statins

A 72‑year‑old patient on atorvastatin and warfarin experiences an unexpected rise in INR to 5.0. Investigation reveals that atorvastatin may inhibit vitamin K epoxide reductase, reducing the regeneration of vitamin K hydroquinone. The clinician reduces the warfarin dose and initiates oral vitamin K 1 mg, achieving an INR of 2.2 within 24 h. This case demonstrates the importance of recognizing drug–drug interactions that affect vitamin K metabolism.

Case Scenario 4 – Vitamin K Reversal in Trauma

A 30‑year‑old male presents to the emergency department with a severe abdominal bleed from a gunshot wound. He is on chronic warfarin therapy for mechanical aortic valve replacement. Intravenous vitamin K 10 mg is administered immediately, and a loading dose of vitamin K 5 mg is given over 30 min. Concurrently, a pack of prothrombin complex concentrates is infused. The patient’s INR normalizes, and he is stabilized for definitive surgical management. This case highlights the role of vitamin K in massive bleeding scenarios.

Problem‑Solving Approach

1. Assess the clinical context: bleeding, surgical need, or drug reversal.
2. Determine the INR or coagulation status.
3. Select the route and dose of vitamin K based on severity.
4. Monitor INR and coagulation parameters at specified intervals.
5. Adjust anticoagulant therapy accordingly, balancing bleeding and thrombotic risks.

Summary/Key Points

• Phytomenadione is a fat‑soluble vitamin essential for post‑translational gamma‑carboxylation of coagulation factors.
• Its pharmacokinetics are characterized by prolonged half‑life and lipoprotein‑mediated distribution.
• Vitamin K must be carefully dosed in the context of warfarin therapy to avoid over‑ or under‑anticoagulation.
• Drug interactions, especially with antibiotics, statins, and other VKAs, can alter vitamin K availability and function.
• Clinical scenarios such as neonatal deficiency, peri‑operative management, and emergency reversal underscore the therapeutic versatility of vitamin K.
• The relationship AUC = Dose ÷ Clearance provides a useful tool for predicting exposure and guiding dose adjustments.
• Monitoring of coagulation parameters, particularly INR, remains the cornerstone of vitamin K therapy management.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.